GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » EV-to-EBITDA

Sareum Holdings (LSE:SAR) EV-to-EBITDA : -7.74 (As of May. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sareum Holdings's enterprise value is £37.37 Mil. Sareum Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £-4.83 Mil. Therefore, Sareum Holdings's EV-to-EBITDA for today is -7.74.

The historical rank and industry rank for Sareum Holdings's EV-to-EBITDA or its related term are showing as below:

LSE:SAR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -247.52   Med: -57.48   Max: -4.41
Current: -7.74

During the past 13 years, the highest EV-to-EBITDA of Sareum Holdings was -4.41. The lowest was -247.52. And the median was -57.48.

LSE:SAR's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs LSE:SAR: -7.74

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Sareum Holdings's stock price is £0.35. Sareum Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.062. Therefore, Sareum Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sareum Holdings EV-to-EBITDA Historical Data

The historical data trend for Sareum Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sareum Holdings EV-to-EBITDA Chart

Sareum Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.95 -13.91 -110.95 -51.88 -20.78

Sareum Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -51.88 - -20.78 -

Competitive Comparison of Sareum Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Sareum Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sareum Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sareum Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sareum Holdings's EV-to-EBITDA falls into.



Sareum Holdings EV-to-EBITDA Calculation

Sareum Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=37.373/-4.829
=-7.74

Sareum Holdings's current Enterprise Value is £37.37 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sareum Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £-4.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sareum Holdings  (LSE:SAR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sareum Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.35/-0.062
=At Loss

Sareum Holdings's share price for today is £0.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sareum Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.062.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sareum Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sareum Holdings (LSE:SAR) Business Description

Traded in Other Exchanges
Address
Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.